Aura Biosciences, Inc. (AURA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 102.78M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 23.16M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -138.08M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $102.78M | (m) | $23.16M | $-138.08M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $94.92M | (m) | $14.63M | $-118.62M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $90.30M | (m) | $14.32M | $-112.79M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $90.74M | (m) | $13.97M | $-113.36M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $85.59M | (m) | $13.03M | $-108.69M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $79.59M | (m) | $12.33M | $-102.84M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $73.30M | (m) | $11.72M | $-96.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $71.25M | (m) | $11.39M | $-93.09M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $69.64M | (m) | $10.96M | $-90.35M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $67.88M | (m) | $9.77M | $-87.86M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $65.23M | (m) | $8.77M | $-84.99M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $58.11M | (m) | $7.98M | $-77.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $53.98M | (m) | $7.38M | $-73.39M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $48.37M | (m) | $6.73M | $-66.93M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $42.24M | (m) | $6.41M | $-60.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $37.06M | (m) | $5.89M | $-54.31M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $32.13M | (m) | $4.73M | $-47.15M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $29.25M | (m) | $3.72M | $-42.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $25.16M | (m) | $2.31M | $-35.25M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $18.04M | (m) | $736.00K | $-22.21M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |